

22nd May 2018

- | | |
|--|---|
| <p>(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> |
|--|---|

Scrip Code: 500087

Scrip Code: CIPLA EQ

- (3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

Sub: Audited Financial Results (Standalone and Consolidated) for the quarter and year ended 31st March 2018

The Board of the Directors of the Company at its meeting held today i.e. 22nd May 2018 has inter-alia approved the Audited Financial Results (standalone and consolidated) for the quarter and year ended 31st March 2018.

Accordingly, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

- (1) Audited Financial Results (standalone and consolidated) for the quarter and year ended 31st March 2018
- (2) Auditors' Report on the Audited Financial Results (standalone and consolidated)
- (3) Declaration from Global Chief Financial Officer


Further, the Board of Directors recommended payment of dividend of Rs.3 per equity share (face value Rs.2 per equity share) for the year 2017-18. The dividend, subject to the approval of shareholders, will be dispatched / credited within 30 days from the date of Annual General Meeting.

: 2 :

The meeting of the Board of Directors of the Company commenced at 9.30 a.m. and concluded at 4.00 p.m.

Thank you,

Yours faithfully,
For Cipla Limited



Rajendra Chopra
Company Secretary

Encl.: as above

- cc: (1) Central Depository Services (India) Ltd.
Marathon Futurex, 25th floor, NM Joshi Marg,
Lower Parel(East), Mumbai – 400 013
- (2) National Securities Depository Ltd.
Trade World, 4th Floor, Kamala Mills Compound,
Senapati Bapat Marg, Lower Parel, Mumbai 400 013

STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2018

(₹ in Crore)

Particulars	Quarter ended			Year ended	
	31-03-2018	31-12-2017	31-03-2017	31-03-2018	31-03-2017
	Audited (Refer note 7)	Unaudited	Audited (Refer note 7)	Audited	Audited
1. Income from operations					
a) Net sales/income from operations (Refer note 2)	2,530.90	2,892.44	2,608.51	11,004.44	10,637.08
b) Other operating income	194.44	77.51	86.66	440.37	337.50
Total income from operations	2,725.34	2,969.95	2,695.17	11,444.81	10,974.58
2. Other income	62.88	40.94	21.19	334.88	129.85
3. Total Income (1+2)	2,788.22	3,010.89	2,716.36	11,779.69	11,104.43
4. Expenses					
a) Cost of materials consumed	762.19	908.78	801.16	3,303.31	2,956.04
b) Purchases of stock-in-trade	269.73	245.85	316.72	1,064.23	1,128.99
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(35.47)	(112.07)	(135.44)	(212.05)	56.27
d) Employee benefits expense	463.27	436.00	394.44	1,785.94	1,728.97
e) Finance costs	4.07	1.90	4.02	11.90	39.20
f) Depreciation, impairment and amortisation expense	132.97	137.88	125.17	529.61	499.97
g) Other expenses	842.27	811.99	874.75	3,307.83	3,256.64
h) Impairment of Investment	-	-	251.41	-	251.41
Total expenses	2,439.03	2,430.33	2,632.23	9,790.77	9,917.49
5. Profit (+)/loss (-) before exceptional item and tax (3-4)	349.19	580.56	84.13	1,988.92	1,186.94
6. Exceptional item (Refer note 3)	77.52	-	-	77.52	-
7. Profit (+)/loss (-) before tax (5-6)	271.67	580.56	84.13	1,911.40	1,186.94
8. Tax expense (net)					
a) Current tax	62.76	157.14	91.30	431.33	311.06
b) Deferred tax	(15.90)	4.88	(33.03)	11.55	(99.06)
Total tax expense	46.86	162.02	58.27	442.88	212.00
9. Net profit (+)/loss (-) after tax (7-8)	224.81	418.54	25.86	1,468.52	974.94
10. Other comprehensive Income/(loss) for the period/year					
a) (i) Items that will not be reclassified to profit or loss	(1.12)	8.32	9.53	2.71	10.60
(ii) Income tax on items that will not be reclassified to profit or loss	0.39	(2.89)	(3.30)	(0.94)	(3.67)
b) (i) Items that will be reclassified to profit or loss	(8.95)	7.64	-	0.72	-
(ii) Income tax on items that will be reclassified to profit or loss	3.10	(2.65)	-	(0.25)	-
Other comprehensive Income/(loss) for the period/year	(6.58)	10.42	6.23	2.24	6.93
11. Total comprehensive income/(loss) for the period/year (9+10)	218.23	428.96	32.09	1,470.76	981.87
12. Paid-up equity share capital (face value ₹ 2/- each)	161.02	160.99	160.90	161.02	160.90
13. Other equity	-	-	-	13,952.50	12,639.61
14. Earnings per share (face value ₹ 2/- each)					
a) Basic (₹)	*2.79	*5.20	*0.32	18.25	12.13
b) Diluted (₹)	*2.79	*5.19	*0.32	18.22	12.11
*Not Annualised					

Notes:

1. The financial result have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5th July 2016.

2. The Government of India introduced the Goods and Service Tax (GST) with effect from 1st July 2017 which subsumes excise duty and various other indirect taxes. As required under Ind AS 18, revenue for the quarter ended 31st March 2018 and 31st December 2017 are reported net of GST. The revenue for year ended 31st March 2018 includes excise duty upto 30th June 2017. Accordingly, income from operations for the quarter and year ended 31st March 2018 are not comparable with corresponding previous periods.

3. The Company had received various notices of demand from the National Pharmaceutical Pricing Authority (NPPA), Government of India, on account of alleged overcharging in respect of certain drugs under the Drugs (Prices Control) Order, 1995 ("DPCO, 1995"). The total demand against the Company as stated in NPPA public disclosure amounts to ₹ 2,606.59 Crore.

Out of the above, demand notices pertaining to a set of products viz, Norfloxacin, Ciprofloxacin, Salbutamol and Theophylline were challenged by the Company (i) in the Hon'ble Bombay High Court on the ground that bulk drugs contained in the said formulations are not amenable to price control, as they cannot be included in the ambit of price control based on the parameters contained in the Drug Policy, 1994 on which the DPCO, 1995 is based and (ii) in the Hon'ble Allahabad High Court on process followed for fixation of pricing norms. These Petitions were decided in favour of the Company and the matters were carried in appeal by the Union of India to the Hon'ble Supreme Court of India. The Hon'ble Supreme Court of India vide its judgment dated 1st August, 2003 restored the said Writ Petitions to the Bombay High Court with directions that the Court will have to consider the Petitions afresh, having due regard to the observations made by the Supreme Court in its judgment. On Union of India filing Transfer Petitions, the Supreme Court ordered transfer of the said petitions restored to the Bombay High Court for being heard along with the Appeal filed against the Allahabad High Court order. Subsequently, vide its Order dated 20th July, 2016 the Hon'ble Supreme Court recalled its transfer order and remanded the Petitions to Bombay High Court for hearing. While remanding the matter to Bombay High Court, the Hon'ble Supreme Court directed Cipla to deposit 50% of the demanded amount with NPPA as stated in its order dated 1st August, 2003 which at that point of time was ₹ 350.15 Crore. Complying with the directions passed by the Hon'ble Supreme Court, Cipla has deposited an amount of ₹ 175.08 Crore which has been received and acknowledged by NPPA. Furthermore, the Company has not received any further notices post such transfer of cases to Bombay High Court. Meanwhile, the Hon'ble Supreme Court of India vide its Order and Judgment dated 21st October, 2016, allowed the Appeals filed by the Government against the Judgment and Order of the Hon'ble Allahabad High Court regarding basis of fixation of retail prices. The said order was specific to fixation of retail prices without adhering to the formula/process laid down in DPCO, 1995. However, the grounds relating to inclusion of certain drugs within the span of price control continues to be sub-judice with the Hon'ble Bombay High Court. The Company has been legally advised that it has a substantially strong case on the merits of the matter, especially under the guidelines/principles of interpretation of the Drug Policy enunciated by the Hon'ble Supreme Court of India. Although, the decision of Hon'ble Supreme Court dated 21st October, 2016 referred above was in favour of Union of India with respect to the appeals preferred by the Government challenging the Hon'ble Allahabad High Court order, basis the facts and legal advice on the matter sub-judice with the Hon'ble Bombay High Court, no provision is considered necessary in respect of the notices of demand received till date aggregating to ₹ 1,736.00 Crore. It may be noted that NPPA in its public disclosure has stated the total demand amount against the Company in relation to the above said molecules to be ₹ 2,282.40 Crore (after adjusting deposit of ₹ 175.08 Crore), however, the Company has not received any further notices beyond an aggregate amount of ₹ 1,736.00 Crore.

For the balance demand (pertaining to the set of products not part of the above mentioned writ proceedings in the Hon'ble Bombay High Court), based on recent correspondence with NPPA and notices received, the Company performed a thorough legal evaluation. Of the total demand received for such products, basis the facts and legal advice, the Company has recorded an additional provision of ₹ 77.52 Crore in profit or loss for the quarter ended 31st March, 2018, disclosed as exceptional item. The total provision against these demands is ₹ 93.94 Crore as of 31st March, 2018.

4. The paid-up equity share capital stands increased to ₹ 161.02 Crore (805,119,164 equity shares of ₹2 each) upon allotment of 174,474 equity shares of ₹ 2 each pursuant to "ESOS 2013-A" during the quarter ended 31st March 2018.

5. The Board of Directors of the Company at its meeting held on 22nd May 2018 has recommended a final dividend of ₹ 3 per equity share (face value of ₹ 2 each) for the financial year ended 31st March 2018. The dividend is subject to approval at the ensuing annual general meeting of the Company.

6. Audited standalone statement of assets and liabilities :-

(₹ in Crore)

Particulars	As at	As at
	31-03-2018	31-03-2017
	Audited	Audited
A. ASSETS		
1. Non-current assets		
(a) Property, plant and equipment	4,158.37	4,095.16
(b) Capital work-in-progress	435.28	540.52
(c) Investment property	0.32	0.32
(d) Intangible assets	161.66	140.10
(e) Intangible assets under development	27.32	15.25
(f) Financial assets		
(i) Investment	3,597.24	3,647.71
(ii) Loans	233.13	215.75
(iii) Others financial assets	40.86	57.08
(g) Advance tax (net)	283.42	192.24
(h) Deferred tax assets (net)	46.80	59.54
(i) Other non-current assets	172.40	298.21
Total non-current assets	9,156.80	9,261.88
2. Current asset		
(a) Inventories	3,037.98	2,653.50
(b) Financial assets		
(i) Investments	1,039.74	638.18
(ii) Trade receivables	2,336.32	1,938.79
(iii) Cash and cash equivalents	217.45	44.60
(iv) Bank balances other than cash and cash equivalents	10.08	13.86
(v) Loans	17.74	9.53
(vi) Other financial assets	470.71	423.42
(c) Other current assets	808.15	623.46
Total current assets	7,938.17	6,345.34
Total assets	17,094.97	15,607.22
B. EQUITY and LIABILITIES		
1. Equity		
(a) Share capital	161.02	160.90
(b) Other equity	13,952.50	12,639.61
Total equity	14,113.52	12,800.51
2. Share application money pending allotment *	-	0.00
Liabilities		
3. Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	-	0.07
(ii) Other financial liabilities	50.11	45.06
(b) Provisions	124.45	125.61
(c) Other non-current liabilities	75.19	80.14
Total non-current liabilities	249.75	250.88
4. Current liabilities		
(a) Financial liabilities		
(i) Borrowings	174.43	324.26
(ii) Trade payables	1,580.02	1,298.21
(iii) Other financial liabilities	273.07	440.75
(b) Other current liabilities	306.00	229.83
(c) Provisions	398.18	262.78
Total current liabilities	2,731.70	2,555.83
Total equity and liabilities	17,094.97	15,607.22


* Nil as at 31st March, 2018 (₹ 11,172 as at 31st March, 2017).

7. The figures for the quarter ended 31st March 2018 and 31st March 2017 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.
8. The figures of the previous year/period have been regrouped/recast to render them comparable with the figures of the current period.
9. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee, which were approved by the Board of Directors at its meeting held on 22nd May 2018.

Mumbai
22nd May 2018



By order of the Board
For CIPLA LIMITED



Umang Vohra
Managing Director and Global Chief Executive Officer

Walker Chandiook & Co LLP

Walker Chandiook & Co LLP
(Formerly Walker, Chandiook & Co)
L-41 Connaught Circus
New Delhi 110001
India

T +91 11 4278 7070
F +91 11 4278 7071

Independent Auditor's Report on Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Cipla Limited

1. We have audited the standalone financial results of Cipla Limited ("the Company") for the year ended 31 March 2018, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to Note 7 to the standalone financial results regarding the figures for the quarter ended 31 March 2018 as reported in these standalone financial results, which are the balancing figures between audited standalone figures in respect of the full financial year and the published standalone year to date figures up to the end of the third quarter of the financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit. These standalone financial results are based on the standalone financial statements for the year ended 31 March 2018 prepared in accordance with the accounting principles generally accepted in India, including Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 ("the Act") and published standalone year to date figures up to the end of the third quarter of the financial year prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, Interim Financial Reporting, specified under Section 133 of the Act, and SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016, which are the responsibility of the Company's management. Our responsibility is to express an opinion on these standalone financial results based on our audit of the standalone financial statements for the year ended 31 March 2018 and our review of standalone financial results for the nine months period ended 31 December 2017.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



Walker Chandiook & Co LLP

3. In our opinion and to the best of our information and according to the explanations given to us, the standalone financial results:
- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016 in this regard; and
 - (ii) give a true and fair view of the standalone net profit (including other comprehensive income) and other financial information in conformity with the accounting principles generally accepted in India including Ind AS specified under Section 133 of the Act for the year ended 31 March 2018.

Walker Chandiook & Co LLP

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013

Ashish Gupta

per **Ashish Gupta**

Partner

Membership No. 504662



Place: New Delhi

Date: 22 May 2018

STATEMENT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST March 2018

(` In Crore)

Particulars	Quarter ended			Year ended	
	31-03-2018	31-12-2017	31-03-2017	31-03-2018	31-03-2017
	Audited (Refer note 9)	Unaudited	Audited (Refer note 9)	Audited	Audited
1. Income from operations					
a) Net sales/income from operations (Refer note 2)	3,495.81	3,834.49	3,487.04	14,750.86	14,280.86
b) Other operating income	202.16	79.33	94.96	468.39	349.38
Total Income from operations	3,697.97	3,913.82	3,582.00	15,219.25	14,630.24
2. Other Income (Refer note 4)	40.01	52.93	22.79	357.65	228.69
3. Total Income (1+2)	3,737.98	3,966.75	3,604.79	15,576.90	14,858.93
4. Expenses					
a) Cost of materials consumed	1,143.26	1,197.38	1,243.52	4,497.16	4,272.66
b) Purchases of stock-in-trade	230.07	320.10	183.28	1,174.20	933.50
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(43.07)	(139.08)	(111.33)	(232.94)	110.96
d) Employee benefits expense	699.01	657.34	638.92	2,690.10	2,633.82
e) Finance costs	35.20	9.15	33.40	114.23	159.38
f) Depreciation, impairment and amortisation expense	284.82	522.35	632.19	1,322.82	1,322.93
g) Other expenses	1,111.83	1,059.42	1,121.37	4,264.35	4,203.51
Total expenses	3,461.12	3,626.66	3,741.35	13,829.92	13,636.76
5. Profit (+)/loss (-) before exceptional item and tax (3-4)	276.86	340.09	(136.56)	1,746.98	1,222.17
6. Exceptional Item (Refer note 3)	77.52	-	-	77.52	-
7. Profit (+)/loss (-) before tax (5-6)	199.34	340.09	(136.56)	1,669.46	1,222.17
8. Tax expense (net)					
a) Current tax	76.11	183.16	149.54	561.06	479.48
b) Deferred tax	(29.96)	(247.39)	(225.24)	(310.95)	(299.72)
Total tax expense	46.15	(64.23)	(75.70)	250.11	179.76
9. Net profit (+)/loss (-) after tax before share of associates (7-8)	153.19	404.32	(60.86)	1,419.35	1,042.41
10. Share of profit (+)/ loss (-) of associates	0.06	(0.87)	(1.93)	(2.78)	(6.99)
11. Net profit (+)/ loss (-) for the period/year (9+10)	153.25	403.45	(62.79)	1,416.57	1,035.42
12. Profit for the period attributable to					
a) Shareholders of the company	178.61	400.51	(61.79)	1,410.53	1,006.39
b) Non- controlling interest	(25.36)	2.94	(1.00)	6.04	29.03
13. Other comprehensive Income/(loss) for the period/year					
a) (i) Items that will not be reclassified to profit or loss	22.90	9.14	7.88	28.41	11.42
(ii) Income tax on items that will not be reclassified to profit or loss	(2.25)	(3.12)	(2.87)	(4.11)	(3.96)
b) (i) Items that will be reclassified to profit or loss	250.38	112.40	(89.98)	382.73	123.89
(ii) Income tax on items that will be reclassified to profit or loss	(8.87)	(5.86)	-	(13.50)	-
Other comprehensive Income/(loss) for the period/year	262.16	112.56	(84.97)	393.53	131.35
14. Total comprehensive income /(loss) for the period/year (11+13)	415.41	516.01	(147.76)	1,810.10	1,166.77
15. Total comprehensive income attributable to					
a) Shareholders of the company	398.96	520.59	(102.99)	1764.52	1,173.67
b) Non- controlling interest	16.45	(4.58)	(44.77)	45.58	(6.90)
16. Paid-up equity share capital (face value ₹2/- each)	161.02	160.99	160.90	161.02	160.90
17. Other equity	-	-	-	14,068.17	12,382.76
18. Earnings per share (face value ₹2/- each)					
a) Basic (₹)	*2.22	* 4.98	*(0.77)	17.53	12.52
b) Diluted (₹)	*2.22	* 4.97	*(0.77)	17.50	12.50
*Not Annualised					

Segment information

(₹ in Crore)

Particulars	Quarter ended			Year ended	
	31-03-2018	31-12-2017	31-03-2017	31-03-2018	31-03-2017
	Audited (Refer note 9)	Unaudited	Audited (Refer note 9)	Audited	Audited
Segment wise revenue and results					
Segment revenue: (Refer note 2)					
a) Pharmaceuticals	3,665.07	3,885.75	3,554.06	15,110.03	14,537.06
b) New ventures	34.26	36.89	28.32	134.78	95.29
Total segment revenue	3,699.33	3,922.64	3,582.38	15,244.81	14,632.35
Less : Inter segment revenue	1.36	8.82	0.38	25.56	2.11
Total Income from operations	3,697.97	3,913.82	3,582.00	15,219.25	14,630.24
Segment result:					
Profit/(loss) before tax and interest from each segment					
a) Pharmaceuticals	357.55	365.67	(7.54)	1,966.48	1,502.47
b) New ventures	(45.49)	(16.43)	(95.62)	(105.27)	(120.92)
Total segment result	312.06	349.24	(103.16)	1,861.21	1,381.55
Less: Finance costs	35.20	9.15	33.40	114.23	159.38
Profit (+)/loss (-) before exceptional item and tax	276.86	340.09	(136.56)	1,746.98	1,222.17
Less: Exceptional item (Refer note 3)	77.52	-	-	77.52	-
Total Profit (+)/loss (-) before tax	199.34	340.09	(136.56)	1,669.46	1,222.17

Segment assets and liabilities

As some of the assets and liabilities are deployed interchangeably across segments, it is not practically possible to allocate those assets and liabilities to each segment. Hence, the details of assets and liabilities have not been disclosed in the above table.

Notes:

1. The financial result have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated 5th July 2016.

2. The Government of India introduced the Goods and Service Tax (GST) with effect from 1st July 2017 which subsumes excise duty and various other indirect taxes. As required under Ind AS 18, revenue for the quarter ended 31st March 2018 and 31st December 2017 are reported net of GST. The revenue for year ended 31st March 2018 includes excise duty up to 30th June 2017. Accordingly, income from operations for the quarter and year ended 31st March 2018 are not comparable with corresponding previous periods.

3. The Company had received various notices of demand from the National Pharmaceutical Pricing Authority (NPPA), Government of India, on account of alleged overcharging in respect of certain drugs under the Drugs (Prices Control) Order, 1995 ("DPCO, 1995"). The total demand against the Company as stated in NPPA public disclosure amounts to ₹ 2,606.59 Crore.

Out of the above, demand notices pertaining to a set of products viz, Norfloxacin, Ciprofloxacin, Salbutamol and Theophylline were challenged by the Company (i) in the Hon'ble Bombay High Court on the ground that bulk drugs contained in the said formulations are not amenable to price control, as they cannot be included in the ambit of price control based on the parameters contained in the Drug Policy, 1994 on which the DPCO, 1995 is based and (ii) in the Hon'ble Allahabad High Court on process followed for fixation of pricing norms. These Petitions were decided in favour of the Company and the matters were carried in appeal by the Union of India to the Hon'ble Supreme Court of India. The Hon'ble Supreme Court of India vide its judgment dated 1st August, 2003 restored the said Writ Petitions to the Bombay High Court with directions that the Court will have to consider the Petitions afresh, having due regard to the observations made by the Supreme Court in its judgment. On Union of India filing Transfer Petitions, the Supreme Court ordered transfer of the said petitions restored to the Bombay High Court for being heard along with the Appeal filed against the Allahabad High Court order. Subsequently, vide its Order dated 20th July, 2016 the Hon'ble Supreme Court recalled its transfer order and remanded the Petitions to Bombay High Court for hearing. While remanding the matter to Bombay High Court, the Hon'ble Supreme Court directed Cipla to deposit 50% of the demanded amount with NPPA as stated in its order dated 1st August, 2003 which at that point of time was ₹ 350.15 Crore. Complying with the directions passed by the Hon'ble Supreme Court, Cipla has deposited an amount of ₹ 175.08 Crore which has been received and acknowledged by NPPA. Furthermore, the Company has not received any further notices post such transfer of cases to Bombay High Court. Meanwhile, the Hon'ble Supreme Court of India vide its Order and Judgment dated 21st October, 2016, allowed the Appeals filed by the Government against the Judgment and Order of the Hon'ble Allahabad High Court regarding basis of fixation of retail prices. The said order was specific to fixation of retail prices without adhering to the formula/process laid down in DPCO, 1995.

However, the grounds relating to inclusion of certain drugs within the span of price control continues to be sub-judice with the Hon'ble Bombay High Court. The Company has been legally advised that it has a substantially strong case on the merits of the matter, especially under the guidelines/principles of interpretation of the Drug Policy enunciated by the Hon'ble Supreme Court of India. Although, the decision of Hon'ble Supreme Court dated 21st October, 2016 referred above was in favour of Union of India with respect to the appeals preferred by the Government challenging the Hon'ble Allahabad High Court order, basis the facts and legal advice on the matter sub-judice with the Hon'ble Bombay High Court, no provision is considered necessary in respect of the notices of demand received till date aggregating to ₹ 1,736.00 Crore. It may be noted that NPPA in its public disclosure has stated the total demand amount against the Company in relation to the above said molecules to be ₹ 2,282.40 Crore (after adjusting deposit of ₹ 175.08 Crore), however, the Company has not received any further notices beyond an aggregate amount of ₹ 1,736.00 Crore.

For the balance demand (pertaining to the set of products not part of the above mentioned writ proceedings in the Hon'ble Bombay High Court), based on recent correspondence with NPPA and notices received, the Company performed a thorough legal evaluation. Of the total demand received for such products, basis the facts and legal advice, the Company has recorded an additional provision of ₹ 77.52 Crore in profit or loss for the quarter ended 31st March, 2018, disclosed as exceptional item. The total provision against these demands is ₹ 93.94 Crore as of 31st March, 2018.

4. During the quarter ended 31st March, 2018, Saba Investment Limited, a subsidiary of the Company completed the disposal of its entire interest in Al Jabal for Drugs and Medical Appliances Company Limited, Yemen ('AJDMS'). Consequently, the foreign currency loss of ₹ 51.17 Crore recorded in other comprehensive income has been reclassified to the statement of profit or loss.

5. The paid-up equity share capital stands increased to ₹ 161.02 Crore (805,119,164 equity shares of ₹2 each) upon allotment of 174,474 equity shares of ₹ 2 each pursuant to "ESOS 2013-A" during the quarter ended 31st March 2018.

6. The Board of Directors of the Company at its meeting held on 22nd May 2018 has recommended a final dividend of ₹ 3 per equity share (face value of ₹ 2 each) for the financial year ended 31st March 2018. The dividend is subject to approval at the ensuing annual general meeting of the Company.

7. The Audited Standalone financial results for the quarter and year ended 31st March 2018 are available on the Company's website i.e. www.cipla.com under Investor Information section and on the stock exchange websites i.e. www.bseindia.com and www.nseindia.com. The key standalone financial information are as under:

Particulars	Quarter ended			Year ended	
	31-03-2018	31-12-2017	31-03-2017	31-03-2018	31-03-2017
	Audited (Refer note 9)	Unaudited	Audited (Refer note 9)	Audited	Audited
Total income from operations	2,725.34	2,969.95	2,695.17	11,444.81	10,974.58
Profit before tax	271.67	580.56	84.13	1,911.40	1,186.94
Profit after tax	224.81	418.54	25.86	1,468.52	974.94

(₹ In Crore)

8. Audited consolidated statement of assets and liabilities:

(₹ In Crore)

Particulars	As at	As at
	31-03-2018	31-03-2017
	Audited	Audited
A. ASSETS		
1. Non-current assets		
(a) Property, plant and equipment	5,315.35	5,008.69
(b) Capital work-in-progress	512.35	719.23
(c) Investment property	1.03	1.74
(d) Goodwill	2,814.74	2,696.67
(e) Other intangible assets	1,819.05	1,784.88
(f) Intangible assets under development	468.98	963.75
(g) Investment in associate	9.62	12.40
(h) Financial assets		
(i) Investments	147.01	123.22
(ii) Loans	41.66	39.48
(iii) Other financial assets	159.14	113.77
(i) Advance tax (net)	388.60	308.28
(j) Deferred tax assets (net)	187.65	168.13
(k) Other non-current assets	181.27	292.20
Total non-current assets	12,046.45	12,232.44
2. Current asset		
(a) Inventories	4,044.70	3,485.28
(b) Financial assets		
(i) Investments	1,102.21	837.39
(ii) Trade receivables	3,102.45	2,563.05
(iii) Cash and cash equivalents	853.46	610.35
(iv) Bank balances other than cash and cash equivalents	112.15	13.86
(v) Loans	19.91	9.53
(vi) Other financial assets	574.82	542.10
(c) Other current assets	1,004.40	674.01
Total current assets	10,814.10	8,735.57
3. Assets classified as held for sale (net)	-	69.06
Total assets	22,860.55	21,037.07
B. EQUITY and LIABILITIES		
1. Equity		
(a) Share capital	161.02	160.90
(b) Other equity	14,068.17	12,382.76
Equity attributable to owner	14,229.19	12,543.66
Non-controlling interest	352.44	438.23
Total equity	14,581.63	12,981.89
2. Share application money pending allotment *	-	0.00
Liabilities		
3. Non-current liabilities		
(a) Financial liabilities		
(i) Borrowings	3,662.11	3,645.36
(ii) Other financial liabilities	50.11	45.06
(b) Provisions	137.92	140.52
(c) Deferred tax liabilities (net)	503.31	756.89
(d) Other non-current liabilities	93.25	93.65
Total non-current Liabilities	4,446.70	4,681.48
4. Current liabilities		
(a) Financial liabilities		
(i) Borrowings	435.87	467.23
(ii) Trade payables	2,119.12	1,571.14
(iii) Other financial liabilities	420.19	642.59
(b) Other current liabilities	226.85	266.36
(c) Provisions	627.11	402.37
(d) Current tax liabilities (Net)	3.08	24.01
Total current liabilities	3,832.22	3,373.70
Total equity and liabilities	22,860.55	21,037.07


* Nil as at 31st March, 2018 (₹ 11,172 as at 31st March, 2017).

9. The figures for the quarter ended 31st March 2018 and 31st March 2017 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.

10. The figures of the previous year/period have been regrouped/recast to render them comparable with the figures of the current period.

11. The above results have been reviewed and recommended to the Board of Directors by the Audit Committee, which were approved by the Board of Directors at its meeting held on 22nd May 2018.

Mumbai
22nd May 2018

By order of the Board
For CIPLA LIMITED

Umang Vohra
Managing Director and Global Chief Executive Officer



Walker Chandiook & Co LLP

Walker Chandiook & Co LLP
(Formerly Walker, Chandiook & Co)
L-41 Connaught Circus
New Delhi 110001
India

T +91 11 4278 7070
F +91 11 4278 7071

Independent Auditor's Report on Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of Cipla Limited

1. We have audited the consolidated financial results of Cipla Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its associate for the year ended 31 March 2018, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to Note 9 to the consolidated financial results regarding the figures for the quarter ended 31 March 2018 as reported in these consolidated financial results, which are the balancing figures between audited consolidated figures in respect of the full financial year and the published consolidated year to date figures up to the end of the third quarter of the financial year. Also, the figures up to the end of the third quarter had only been reviewed and not subjected to audit. These consolidated financial results are based on the consolidated financial statements for the year ended 31 March 2018 prepared in accordance with the accounting principles generally accepted in India, including Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 ("the Act") and published consolidated year to date figures up to the end of the third quarter of the financial year prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, Interim Financial Reporting, specified under Section 133 of the Act, and SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016, which are the responsibility of the Holding Company's management. Our responsibility is to express an opinion on these consolidated financial results based on our audit of the consolidated financial statements for the year ended 31 March 2018 and our review of consolidated financial results for the nine month period ended 31 December 2017.



2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors on separate financial statements of the subsidiaries and an associate, the consolidated financial results:
 - (i) include the financial results for the year ended 31 March 2018, of the entities as mentioned in Annexure I;
 - (ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016 in this regard; and
 - (iii) give a true and fair view of the consolidated net profit (including other comprehensive income) and other financial information in conformity with the accounting principles generally accepted in India including Ind AS specified under Section 133 of the Act for the year ended 31 March 2018.
4. We did not audit the financial statements of 45 subsidiaries, whose financial statements reflect total assets of ₹ 3,333.83 crore and net assets of ₹ 1,100.08 crore as at 31 March 2018, and total revenues of ₹ 3,094.71 crore for the year ended on that date, as considered in the consolidated financial results. The consolidated financial results also include the Group's share of net loss (including other comprehensive income) of ₹ 2.78 crore for the year ended 31 March 2018, as considered in the consolidated financial results, in respect of an associate, whose financial statements have not been audited by us. These financial statements have been audited by other auditors whose report been furnished to us by the management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate, and our report in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circulars CIR/CFD/CMD/15/2015 dated 30 November 2015 and CIR/CFD/FAC/62/2016 dated 5 July 2016, in so far as it relates to the aforesaid subsidiaries and an associate, are based solely on the report of such other auditors.



Walker Chandiook & Co LLP

Further, of these subsidiaries and associate, 43 subsidiaries are located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been audited by other auditors under generally accepted auditing standards applicable in their respective countries. The Holding Company's management has converted the financial statements of such subsidiaries and associates located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Holding Company's management. Our opinion, in so far as it relates to the financial information of such subsidiaries and an associate located outside India, is based on the reports of other auditors and the conversion adjustments prepared by the management of the Holding Company and audited by us.

Our opinion on the consolidated financial results is not modified in respect of this matter with respect to our reliance on the work done by and the reports of the other auditors.

Walker Chandiook & Co

For Walker Chandiook & Co LLP

Chartered Accountants

Firm Registration No.: 001076N/N500013

Ashish Gupta

per **Ashish Gupta**

Partner

Membership No. 504662



Place: New Delhi

Date: 22 May 2018

Walker Chandiook & Co LLP

Annexure I to Independent Auditor's Report on Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

Annexure I

List of subsidiaries as at 31 March 2018

1. Goldencross Pharma Private Limited, India
2. Meditab Specialities Private Limited, India
3. Cipla BioTec Private Limited, India
4. Jay Precision Pharmaceuticals Private Limited, India
5. Cipla Health Limited, India
6. Medispray Laboratories Private Limited, India
7. Sitec Labs Private Limited, India
8. Cipla Medpro South Africa (Proprietary) Limited, South Africa
9. Cipla Holding B.V., Netherlands
10. Cipla (EU) Limited, United Kingdom
11. Saba Investment Limited, United Arab Emirates
12. Meditab Specialities New Zealand Ltd (up to 10 July 2017), New Zealand
13. Cipla (UK) Limited, United Kingdom
14. Cipla Australia Pty. Limited, Australia
15. Meditab Holdings Limited, Mauritius
16. Cipla İlaç Ticaret Anonim Şirketi, Turkey
17. Cipla USA, Inc., United States of America
18. Cipla Kenya Limited, Kenya
19. Cipla Malaysia Sdn. Bhd., Malaysia
20. Cipla Europe NV, Belgium
21. Cipla Quality Chemical Industries Limited, Uganda
22. Cipla Brasil Importadora E Distribuidora De Medicamentus Ltda., Brazil
23. Galilee Marketing Proprietary Limited, South Africa
24. Inyanga Trading 386 Proprietary Limited, South Africa
25. Xeragen Laboratories Proprietary Limited, South Africa
26. Cipla Medpro Holdings Proprietary Limited, South Africa
27. Cape to Cairo Exports Proprietary Limited, South Africa
28. Cipla Vet Proprietary Limited (up to 1 June 2017), South Africa
29. Cipla Pharma Nigeria Ltd (up to 9 January 2018), Nigeria
30. Cipla Dibcare Proprietary Limited, South Africa
31. Cipla Life Sciences Proprietary Limited, South Africa
32. Cipla-Medpro Proprietary Limited, South Africa
33. Cipla-Medpro Distribution Centre Proprietary Limited, South Africa
34. Cipla Medpro Botswana Proprietary Limited, South Africa
35. Cipla Agimed Proprietary Limited, South Africa
36. Cipla Algeria, Algeria
37. Cipla Biotec South Africa (Pty) Limited, South Africa
38. Cipla Nutrition Proprietary Limited, South Africa
39. Medpro Pharmaceutica Proprietary Limited, South Africa
40. Med Man Care Proprietary Limited, South Africa
41. Breathe Free Lanka (Private) Limited, Sri Lanka
42. Medica Pharmaceutical Industries Company Limited, Yemen
43. Al-Jabal For Drugs and Medical Appliances Company Limited (up to 26 March 2018), Yemen




Walker Chandiook & Co LLP

Annexure I to Independent Auditor's Report on Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Continued)

44. Cipla (Mauritius) Limited, Mauritius
45. Cipla FZE, United Arab Emirates
46. Cipla Croatia d.o.o (up to 19 Jan 2018), Croatia
47. Cipla Pharma Lanka (Private) Limited, Sri Lanka
48. Cipla Maroc SA, Morocco
49. Cipla Middle East Pharmaceuticals FZ-LLC, United Arab Emirates
50. Quality Chemicals Limited, Uganda
51. Cipla Philippines, Inc., Philippines
52. InvaGen Pharmaceuticals, Inc., United States of America
53. Exelan Pharmaceuticals, Inc., United States of America
54. Anmarate Proprietary Limited, South Africa
55. Cipla Technologies, LLC, United States of America

List of associate as at 31 March 2018

1. Stempeutics Research Private Limited, India





22nd May 2018

- | | |
|---|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051</p> |
|---|---|

Scrip Code: 500087

Scrip Code: CIPLA EQ

- (3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Dear Sirs,

We, hereby confirm and declare that the Statutory Auditors of the Company i.e. Walker Chandiook & Co LLP, Chartered Accountants, have issued the audit report on Standalone and Consolidated Financial Results of the Company for the quarter and year ended 31st March 2018 with unmodified opinion.

For Cipla Limited

Kedar Upadhye

Global Chief Financial Officer